

# Phospholamban Modulates the Functional Coupling between Nucleotide Domains in Ca-ATPase Oligomeric Complexes in Cardiac Sarcoplasmic Reticulum<sup>†</sup>

Linda T. L. Chen,<sup>‡</sup> Qing Yao,<sup>§</sup> Thereza A. Soares, Thomas C. Squier, and Diana J. Bigelow\*

Biological Sciences Division, Pacific Northwest National Laboratory, P.O. Box 999, Richland, Washington 99352

Received November 21, 2008; Revised Manuscript Received February 2, 2009

**ABSTRACT:** Oligomeric interactions between Ca-ATPase polypeptide chains and their modulation by phospholamban (PLB) were measured in native cardiac sarcoplasmic reticulum (SR) microsomes. Progressive modification of Lys<sup>514</sup> with fluorescein 5-isothiocyanate (FITC), which physically blocks access to the nucleotide binding site by ATP, demonstrates that Ca-ATPase active sites function independently of one another prior to the phosphorylation of PLB. However, upon cAMP-dependent protein kinase (PKA) phosphorylation of PLB, a second-order dependence between residual enzyme activity and the fraction of active sites is observed, consistent with a dimeric functional complex. Complementary distance measurements were made using FITC or 5-iodoacetamidofluorescein (IAF) bound to Cys<sup>674</sup> within the N- or P-domains, respectively, to detect structural coupling within oligomeric complexes. Accompanying the phosphorylation of PLB, neighboring Ca-ATPase polypeptide chains exhibit a  $4 \pm 2$  Å decrease in the proximity between FITC sites within the N-domain and a  $9 \pm 3$  Å increase in the proximity between IAF sites within P-domains. Thus, the phosphorylation of PLB induces spatial rearrangements between the N- and P-domain elements of proximal Ca-ATPase polypeptide chains which restore functional interactions between neighboring polypeptide chains and, in turn, result in increased rates of catalytic turnover. These results are interpreted in terms of a structural model, calculated through optimization of shape complementarity, desolvation, and electrostatic energies, which suggests a dimeric arrangement of Ca-ATPase polypeptide chains through the proximal association of N-domains that accommodates interaction with PLB. We suggest that the phosphorylation of PLB acts to release constraints involving interdomain subunit interactions that enhance catalytically important N-domain motions.

Ca-ATPases function to maintain low cytoplasmic calcium levels, acting to resequester calcium into the sarcoplasmic reticulum (SR) lumen after each contractile event, thus controlling relaxation rates in the heart and other muscle cells. Coexpression of the regulatory protein phospholamban (PLB)<sup>1</sup> in slow-twitch skeletal muscle and the heart permits the modulation of Ca-ATPase transport function and thus the force and rate of muscle contraction. Specifically, in response to  $\beta$ -adrenergic stimulation, the activation of cAMP-dependent protein kinase (PKA) results in the phosphorylation of Ser<sup>16</sup> in PLB, which releases inhibitory interactions

with the Ca-ATPase that enhance transport activity at submicromolar (nonsaturating) calcium level. This release of inhibition is not accompanied by dissociation of PLB from the Ca-ATPase; rather, protein–protein interactions within the intact PLB–ATPase complex are altered (1–3). PLB imposes restrictions on large-scale domain rearrangements of the Ca-ATPase that are critical to the formation of the second high-affinity calcium binding site associated with cooperative calcium binding and ATP utilization (1, 4). PLB phosphorylation acts to stabilize the hinge region within PLB between the transmembrane and cytosolic helices. At the same time the overall dimensions of the cytosolic domain of PLB are reduced, resulting in release of the PLB–ATPase interactions that restrict catalytically important motions of the nucleotide (N) domain in the Ca-ATPase (1, 5–8).

Specific binding interfaces between PLB and transmembrane helices TM2, TM4, and the nucleotide (N) domain of the Ca-ATPase have been identified using both cross-linking (9–11) and molecular modeling approaches (9, 12–15) (Figure 1). Cross-linking efficiencies are diminished upon calcium binding to the Ca-ATPase; in combination with kinetic measurements, these results indicate that PLB stabilizes the apo form of the Ca-ATPase (i.e., the E2 state) through specific binding interactions that restrict large-scale movements associated with calcium binding (15–17). Cryoelectron microscopy structural measurements indicate that one PLB is able to interact with two Ca-ATPase polypeptide


<sup>†</sup> This work was supported by the National Institutes of Health (HL64031). Pacific Northwest National Laboratory is operated for the Department of Energy by Battelle Memorial Institute under contract DE-AC05-76RLO 1830.

\* Correspondence should be addressed to this author. E-mail: diana.bigelow@pnl.gov. Tel: (509) 376-2378. Fax: (509) 372-1632.

<sup>‡</sup> Present address: Invitrogen Corp., 542 Flynn Rd., Camarillo, CA 93010.

<sup>§</sup> Present address: The Masonic Cancer Center, University of Minnesota, MMC 806, 420 Delaware St. SE, Minneapolis, MN 55455.

<sup>1</sup> Abbreviations: A-domain, actuator domain; CPK, Corey–Pauling–Koltun coloring conventions; DTT, dithiothreitol; EGTA, ethylene glycol bis( $\beta$ -aminoethyl ether)-N,N,N',N'-tetraacetic acid; FITC, fluorescein 5-isothiocyanate; FRET, fluorescence resonance energy transfer; IAF, 5-iodoacetamidofluorescein;  $\beta$ -ME, 2-mercaptoethanol; MOPS, 3-(N-morpholino)propanesulfonic acid; N-domain, nucleotide binding domain; P-domain, phosphorylation domain; NMA, normal-mode analysis; PKA, cAMP-dependent protein kinase; PLB, phospholamban; SERCA, sarco/endoplasmic reticulum Ca-ATPase; TM, transmembrane.



**FIGURE 1:** Structures of the Ca-ATPase and PLB. The structure of the Ca-ATPase (1su4.pdb) depicts the headpiece, corresponding to discrete structural elements associated with the A-domain (residues 1–43 and 124–235, purple), N-domain (residues 360–600, pink), and P-domain (residues 330–359 and 601–739, green) relative to the transmembrane helices TM1–TM2 (residues 44–123, cyan), TM3–TM6 (residues 239–329 and 740–821, red), and TM7–TM10 (residues 831–994, gray), where domain boundaries are as previously described (72). The ten NMR structures of a PLB monomer are shown on the right (1fjk.pdb). Highlighted in the structures of Ca-ATPase and PLB are (yellow space-filling) side chains that have been identified through covalent cross-linking experiments which involve both endogenous amino acids (C or K) or engineered cysteines at sites in TM2 (i.e., V<sup>89</sup>), TM4 (T<sup>317</sup>, C<sup>318</sup>, L<sup>321</sup>, and K<sup>328</sup>), and the N-domain (i.e., K<sup>397</sup>DDKPV<sup>402</sup>) of the Ca-ATPase with sites on PLB (i.e., I<sup>45</sup>–L<sup>52</sup>, L<sup>31</sup>, N<sup>30</sup>, N<sup>27</sup>, Q<sup>23</sup>, or K<sup>3</sup>) (9–11). Labeling sites are indicated for FITC modification at K<sup>514</sup>/K<sup>515</sup> in the N-domain and IAF modification at C<sup>674</sup> in the P-domain of the Ca-ATPase.

chains (18). These structural measurements are consistent with functional measurements in both reconstituted and native SR membranes that have demonstrated that one PLB complexed with two Ca-ATPase is sufficient for complete inhibition (19, 20). These results suggest that PLB modulates allosteric interactions between Ca-ATPase polypeptide chains within an oligomeric complex (16, 21). Inhibition of enzyme activity is suggested to involve the modulation of specific contact points between the N-domains of neighboring Ca-ATPase polypeptide chains that act to uncouple the conformational coupling between oligomeric complexes that accelerate enzyme turnover through enhanced domain movements. To investigate this latter hypothesis, we have used fluorescein 5-isothiocyanate (FITC) to block ATP access to the active site of the Ca-ATPase to assess the functional role of oligomeric interactions between Ca-ATPase polypeptide chains in native SR microsomes isolated from porcine hearts. Complementary measurements used fluorescence resonance energy transfer (FRET) to assess changes in the distances between fluorescein moieties, site-specifically bound to either the nucleotide (N) or phosphorylation (P) domain elements of the Ca-ATPase, in response to the phosphorylation of PLB by cAMP-dependent protein kinase. Our results indicate that the Ca-ATPase functions as an oligomeric complex, whose structural coupling is disrupted by PLB. Phosphorylation of PLB by PKA results in large-scale domain movements that

act to restore the functional coupling between Ca-ATPase polypeptide chains.

## EXPERIMENTAL PROCEDURES

**Materials.** ATP (disodium salt), cAMP, cAMP-dependent protein kinase (PKA), calcium ionophore A23187, nonionic detergent C<sub>12</sub>E<sub>8</sub>, EGTA, and fluorescein 5-isothiocyanate (FITC) were purchased from Sigma (St. Louis, MO). 5-Iodoacetamidofluorescein (IAF) was obtained from Invitrogen Molecular Probes (Eugene, OR). Calyculin A was purchased from Calbiochem (La Jolla, CA). MOPS was purchased from Thermal Fischer Scientific (Waltham, MA). Alkaline phosphatase was purchased from Worthington Biochemical Corp. (Lakewood, NJ). CaCl<sub>2</sub> standard solutions were purchased from VWR International (West Chester, PA).

**Preparation of Cardiac SR.** SR membranes were isolated from pig hearts by several steps of differential centrifugation for removal of cell debris, mitochondria, and myosin prior to enrichment of the SR membrane vesicles on a sucrose density gradient containing 5–7% dextran T-10 as detailed previously (22). The protein concentration was determined by the Amido Schwartz assay.

**PLB Phosphorylation and Dephosphorylation.** For fluorescence measurements, activation by cAMP-dependent protein kinase (PKA) involved addition of 1  $\mu$ M cAMP, 80  $\mu$ g/mL bovine heart PKA, and 0.1 mM ATP added to SR microsomes in a buffered solution containing 0.5  $\mu$ M free calcium for at least 10 min prior to making measurements. Maximal levels of phosphorylated PLB (4–5 nmol/mg of SR) are retained for at least 2 h, allowing for stable fluorescence measurements which require only 10 min (22). For Ca-ATPase activity assays, cAMP and PKA were added to the assay medium for 10 min to ensure temperature stabilization prior to addition of 5 mM ATP to start Ca-ATPase activity reaction. For dephosphorylation of PLB, samples were similarly pretreated for 10 min with 7  $\mu$ g/mL PKA inhibitor (calyculin A) and 5 units/mL alkaline phosphatase type VII-NL (Sigma).

**ATPase Activity Assay.** Calcium-dependent ATPase activity was measured at 25 °C as previously described, using SR microsomes (0.1 mg/mL) in 25 mM MOPS (pH 7.0), 0.1 M KCl, 5 mM MgCl<sub>2</sub>, 6  $\mu$ M A23187, 0.1 mM EGTA, and sufficient calcium to yield the desired free calcium concentration (23). Basal activity was assayed in the presence of 1 mM EGTA with no added calcium. Steady-state levels of phosphorylated Ca-ATPase were measured from [ $\gamma$ -<sup>32</sup>P]ATP as previously described (22).

**Gel Electrophoresis.** Sodium dodecyl sulfate–polyacrylamide gel electrophoresis was performed by the method of Laemmli (24), using 7.5% acrylamide gels with a 3% stacking gel. Fluorescence was detected prior to staining with Coomassie Blue under ultraviolet light ( $\lambda_{\text{ex}}$  = 366 nm), where fluorescence was detected subsequent to a Corning 3-70 long-pass filter.

**Derivatization of the SR Ca-ATPase.** The Ca-ATPase was specifically derivatized using either fluorescein 5-isothiocyanate (FITC) or 5-iodoacetamidofluorescein (IAF), essentially as previously described (25, 26). Specific labeling of Lys<sup>514</sup> in SERCA2a involved incubation with the indicated amounts of FITC for 10 min with cardiac microsomes (2.0 mg/mL) in 10 mM Tris (pH 9.2), 0.1 M KCl, and 0.3 M sucrose at

22 °C. The reaction was quenched by a 10-fold dilution into an ice-cold buffer A comprised of 20 mM MOPS (pH 7.0), 0.3 M sucrose, and 1 mg/mL bovine serum albumin followed by centrifugation (100000g); the resulting pellet was resuspended in 20 mM MOPS, pH 7.0, and 0.3 M sucrose. Specific labeling of Cys<sup>674</sup> in SERCA2a with IAF required the modification of other reactive cysteines through the preincubation of cardiac microsomes (2 mg/mL) in buffer A with *N*-ethylmaleimide (NEM) (80 μM) for 30 min at 22 °C. Following centrifugation at 100000g to remove unbound NEM, pellets were resuspended in buffer A and diluted to 2 mg/mL prior to the addition of IAF. Following 10 min of incubation, samples were diluted 10-fold with buffer A. The stoichiometries of bound FITC or IAF were measured in the presence of 1% sodium dodecyl sulfate and 0.1 M NaOH where  $\epsilon_{491} = 80000 \text{ M}^{-1} \text{ cm}^{-1}$ .

**Fluorescence Measurements.** FITC- or IAF-labeled Ca-ATPase was excited at 488 nm, and emitted fluorescence was detected after a Schott OG-530 long-pass filter using a Glan-Thompson polarizer set parallel or perpendicular to the vertically polarized excitation light. Fluorescence lifetime measurements utilized a Pockels cell to modulate the light, measuring both phase lag and demodulation of the modulated light relative to a glycogen standard, as previously described (27), where data were fit using the method of nonlinear least squares to a sum of two exponential decays (28). Steady-state polarization (*P*) was calculated from the ratio of the fluorescence intensities (*I*) measured with the polarizers on the excitation and emission sides of the sample in the vertical (v) or horizontal (h) position. *P* is calculated from the equation:

$$P = \frac{I_{vv} - gI_{vh}}{I_{vv} + gI_{vh}} \quad (1)$$

where  $g = I_{hv}/I_{hh}$  and corrects for the differing sensitivities of the detection system for vertically and horizontally polarized light (29).

**Analysis of Spatial Separation between Fluorescein-Labeled Ca-ATPase Polypeptide Chains.** Decreases in the emission anisotropy [ $A = (1/P - 1/3)^{-1}$ ] of fluorescein bound to the Ca-ATPase upon increasing the labeling stoichiometry result from fluorescence resonance energy transfer (FRET) and provide information regarding subunit interactions between neighboring SERCA subunits (20, 30, 31).

$$A(A_0, A_s, A_t) = \sum_{r=1}^n \frac{(N-1)!}{(r-1)!(N-r)!} (f)^{r-1} (1-f)^{N-r} \times \left[ A_0 - (A_0 - A_s) \frac{\frac{(r-1)(A_0 - A_s)}{(N-1)(A_s - A_t)}}{1 + \frac{(r-1)(A_0 - A_s)}{(N-1)(A_s - A_t)}} \right] \quad (2)$$

In this equation,  $A(A_0, A_s, A_t)$  is the measured emission anisotropy, *f* is the labeling stoichiometry of fluorescein bound per mole of the Ca-ATPase, *N* is the apparent oligomeric size of the Ca-ATPase,  $A_0$  is the initial emission anisotropy in the absence of FRET,  $A_s$  is the emission anisotropy when all fluorescein labeling sites within the Ca-ATPase oligomeric complex are saturated, and  $A_t$  is the emission anisotropy after one FRET event. Fitting the data

involves incrementally adjusting *N* by integral values and solving for  $A_0$ ,  $A_s$ , and  $A_t$ , which provide information regarding both the spatial separation and orientation of chromophores on adjacent Ca-ATPase polypeptide chains. Knowledge of  $A_0$ ,  $A_s$ ,  $A_t$ , and the Förster distance ( $R_0$ ) permits calculation of the average separation ( $r_{av}$ ) between fluorescein chromophores and the effective angle between donor and acceptor dipoles ( $\theta_{av}$ ) (30), where

$$r_{av} = R_0 \left[ \frac{2A_t/A_0 + 1}{3} \right]^2 \left[ \frac{A_s - A_t}{(A_0 - A_s)(N-1)} \right] \quad (3)$$

and

$$\cos \theta_{av} = \frac{2A_t}{3A_0} + \frac{1}{3} \quad (4)$$

In fitting the emission anisotropy as a function of the fractional saturation of fluorophore sites, various integral values of *N* were specified, and for each value, a three-parameter fit was performed with optimal values of  $A_0$ ,  $A_t$ , and  $A_s$ . Minimal chi-squared values of the fits indicated which value of *N* best described the data.

Solvent accessibilities of FITC or IAF were measured as a function of the quencher concentration [Q], using potassium iodide or acylamide, according to the Stern–Volmer equation:

$$F_0/F = 1.0 + K_{SV}[Q] \quad (5)$$

where  $F_0$  and *F* are fluorescence in the absence and presence of quencher, respectively.  $K_{SV}$  is the slope of a plot of  $F_0/F$  versus [Q] and is related to the solvent accessibility of the fluorophore.

**Molecular Docking of the Ca-ATPase Dimer.** The Ca-ATPase dimer was modeled from the three-dimensional structure of the SERCA1 isoform, 1kju.pdb (32), the same structure previously used to propose a low-resolution (8–10 Å), ribbon-like model of the dimer from cryoelectron microscopy image experiments (33). The two monomers were docked with the ZDOCK software which uses a fast Fourier transform to exhaustively search the entire rotational and translational space of one monomer with respect to the other that remains fixed at the origin (34). The rotational search is performed by explicitly rotating the ligand around each of its three Cartesian angles by a certain increment. For every rotation, the algorithm rapidly scans the translational space using fast Fourier transform. The best structures are evaluated on the basis of shape complementarity, desolvation energy, and electrostatics (35). Based on the cryoelectron microscopy of the Ca-ATPase (33) and FRET measurements, generated structures were required to meet some basic criteria regarding reasonable structures. For example, (i) the two Ca-ATPase monomers should be aligned along an axis perpendicular to the plane of the membrane bilayers and (ii) the two monomers should be related by a 2-fold rotational center of symmetry; additionally, (iii) the dimer interactions should not interfere with PLB bound to the Ca-ATPase as established by separate docking calculations (see below). These three criteria were used to choose the best dimer structural model out of the 2000 solutions generated from the ZDOCK molecular docking algorithm.



**Molecular Docking of PLB to Ca-ATPase Monomer.** Molecular docking calculations, using the program AutoDock, were carried out for the X-ray structures of the SERCA1 isoform of the Ca-ATPase (1su4.pdb and 2agv.pdb) solved at 2.6 Å and the NMR structure of PLB (1fjk.pdb) (36–39) using the program AutoDock (40). The transmembrane helix (domain II) and mobile N-terminal region (domain Ia) of PLB were separately docked to the Ca-ATPase structure to eliminate any conformational bias imposed by the initial configuration of the interhelical loop (domain Ib) of PLB. This region is known to be very flexible, allowing multiple orientations of domain Ia with respect to domain II. The helical domains of PLB were treated as rigid bodies. Polar hydrogens and protonation states were assigned to the experimental coordinates, i.e., pH 7.0. The AMBER united atom charges and solvation parameters were added to the final protein file (41). The grid maps were calculated using AutoGrid version 4.1 (40). The grids were chosen to be sufficiently large to include not only the active site but also significant portions of the surrounding surface. Grid dimensions were  $126 \times 126 \times 126$  Å, with a spacing of 0.5 Å between the grid points and the center close to the C $\alpha$  of residues Tyr<sup>317</sup> and Lys<sup>397</sup>. The Lamarckian genetic search algorithm was chosen for the molecular docking calculations with the following run parameters (see refs 40, 42, and 43 for details): the initial population of random individuals with a size of 50 individuals; a maximum number of  $1.5 \times 10^6$  energy evaluations; a maximum number of generations of 27000; mutation and crossover rates of 0.02 and 0.08, respectively. Elitism, which ensures that the top individual always survives into the next generations, was applied. A maximum of 300 iterations per local search was used. The probability of performing a local search on an individual was 0.06, where the maximum number of consecutive successes or failures before doubling or halving the search step was 4. A set of 100 docking simulations were performed for each domain of phospholamban; the results were clustered with a root-mean-square positional deviation of 2.0 Å.

## RESULTS

**Selective Labeling of the Ca-ATPase by FITC.** To investigate the functional coupling between Ca-ATPase polypeptide chains, we have measured the loss of catalytic activity with selective inactivation of Ca-ATPase polypeptide chains in the presence of PLB expressed in their native environment of cardiac SR membranes (44). This approach builds upon prior measurements demonstrating that FITC specifically and covalently modifies Lys<sup>514</sup> in SERCA2a or the analogous site in SERCA1 (Lys<sup>515</sup>) to sterically block nucleotide binding (45, 46). Following FITC labeling, the Ca-ATPase remains conformationally competent as evidenced by the observation that small phosphoryl ester substrates (e.g., acetyl phosphate) are able to couple phosphoenzyme formation to calcium transport, albeit at much reduced catalytic rates (47, 48). Thus FITC modification provides a means to selectively titrate the number of available active sites without inducing tertiary structural changes associated with physical methods of inactivation (e.g., radiation inactivation) (49). In agreement with earlier results, FITC is observed to selectively modify the Ca-ATPase in cardiac SR microsomes at a site that is protected by the inclusion of nonhydrolyzable ATP analogues




FIGURE 2: Specific fluorescent labeling of the Ca-ATPase. Fluorescent signals (right lanes) and Coomassie blue protein stain (left lanes) for FITC-labeled or IAF-labeled proteins following SDS-PAGE (7.5% acrylamide) separation of microsomal proteins (50  $\mu$ g) isolated from porcine ventricles. Positions of protein standards are indicated, which correspond to galactosidase (116 kDa), phosphorylase *a* (97 kDa), albumin (66 kDa), ovalbumin (45 kDa), carbonic anhydrase (31 kDa), and trypsin inhibitor (21 kDa).




FIGURE 3: Functional effects of covalent modification of porcine SERCA2a in cardiac sarcoplasmic reticulum. Calcium-dependent ATPase activities (open symbols) or stoichiometries of fluorophore (FITC, panel A; IAF, panel B) labeling (closed symbols) were measured for cardiac SR microsomes in the absence (squares, circles) or presence (triangles) of 6 mM AMPPCP to block access to the nucleotide binding cleft. Specific labeling of Lys<sup>514</sup>, by FITC, or Cys<sup>674</sup>, by IAF, in SERCA2a of cardiac SR membranes was performed, and calcium-dependent ATPase activities were measured (25 °C) as described in Experimental Procedures.

(Figures 2 and 3A). Maximal FITC incorporation corresponds to  $3.5 \pm 0.1$  nmol/mg of SR protein (Figure 3A), which is consistent with measurements of both Ca-ATPase abundance in cardiac SR microsomes based on its relative density on Coomassie-stained gels, about 35% of the total protein, and levels of steady-state phosphoenzyme formation ( $2.0 \pm 0.3$  nmol/mg of SR protein). Similar stoichiometries were




FIGURE 4: Phospholamban modulates functional coupling between Ca-ATPase polypeptide chains. Rates of ATP hydrolysis were measured for the Ca-ATPase in cardiac SR vesicles in the absence (open circles) or upon addition of either cAMP (1  $\mu$ M) and PKA (80  $\mu$ g/mL) (closed circles) or heparin (100  $\mu$ M) (open triangle) in comparison with skeletal SR prior to (closed squares) or following (open squares) solubilization with C<sub>12</sub>E<sub>8</sub> (6  $\mu$ M). Access to the ATP binding cleft was blocked through the modification of either Lys<sup>515</sup> (skeletal) or Lys<sup>514</sup> (cardiac) with FITC to yield variable amounts of unmodified Ca-ATPase ( $F$ ). Maximal stoichiometries of FITC were  $3.4 \pm 0.1$  and  $6.3 \pm 0.1$  nmol/mg, respectively, for cardiac and skeletal microsomes (see Figures S1 and S2 in Supporting Information). Inset: Normalized activity for cardiac SR in the presence of cAMP and PKA as a function of the squared concentration of unmodified (active) Ca-ATPase.

obtained by specific derivatization of Cys<sup>674</sup> by 5-iodoacetamidofluorescein (IAF), where maximal levels of modification correspond to  $3.7 \pm 0.2$  nmol/mg of microsomal protein (Figures 2 and 3B). IAF, in contrast to FITC, binds at a nonfunctional site as evidenced by the lack of Ca-ATPase inhibition upon IAF modification (25, 45, 46).

**PLB Modulates Functional Interactions between Ca-ATPase Chains.** Functional interactions between individual Ca-ATPase polypeptide chains under different conditions were examined by varying the ratio of modified-to-unmodified active sites in relation to the resulting ATPase activities. For example, cardiac SR exhibits a linear one-to-one relationship between the fraction of unmodified active sites and ATPase activity (Figure 4). In comparison, after PKA-mediated phosphorylation of PLB, a nonlinear and second-order relationship is observed (i.e., activity =  $F^2$ ), indicating that for every nucleotide site modified by FITC two Ca-ATPases are inactivated. Further, a virtually identical functional dependency is apparent in cardiac SR following addition of heparin, which provides an alternate means of enzyme activation by electrostatic charge disruption of interactions between PLB and the Ca-ATPase (50).

The functional inactivation of cardiac SR was compared with that of skeletal SR in which the homologous SERCA1 isoform is expressed in the absence of PLB. FITC-modified (at Lys<sup>515</sup>) SERCA1 of skeletal SR exhibits a second-order functional inactivation identical to that of the Ca-ATPase in PKA-activated cardiac SR (Figures 4 and S1) (51). To test if these second-order inactivation profiles depend on interactions between Ca-ATPase polypeptide chains, parallel experiments were performed using skeletal SR solubilized with the nonionic detergent C<sub>12</sub>E<sub>8</sub> under conditions previously demonstrated to result in SERCA1 monomers (52). Of note, under these conditions that disrupt protein interactions, full activity of unmodified SERCA1 was retained. In the case of C<sub>12</sub>E<sub>8</sub>-solubilized skeletal SR, the FITC inactivation profile reverts to first order (Figure 4). Thus, the one-to-one

relationship between enzyme function and active unmodified Ca-ATPase polypeptide chains in cardiac SR vesicles suggests that the SERCA2a active sites function independently until PLB is phosphorylated, upon which interactions between the two active sites are restored. Together, these results suggest that the phosphorylation state of PLB modulates the functional coupling between nucleotide sites on two Ca-ATPase polypeptide chains within an oligomeric complex (20).

**Modulation of Ca-ATPase Structure by PLB.** To directly address if modulation of functional coupling between active sites is dependent on changes in physical interactions between individual Ca-ATPases, we have utilized FRET measurements between the same fluorophore (homotransfer) on individual Ca-ATPase polypeptide chains in cardiac SR. This approach has previously been demonstrated to be sensitive to the spatial proximity of nearest-neighbor Ca-ATPase proteins in skeletal SR (30). In the present study, measurements were made from the perspective of two distinct sites on SERCA2a, i.e., Lys<sup>514</sup> within the N-domain, modified by FITC, and Cys<sup>674</sup> within the P-domain, modified by IAF. For homotransfer measurements, fluorescein serves as an optimal fluorophore due to both its large quantum yield and extinction coefficient but small Stokes shift. Thus a substantial spectral overlap between emission and absorption spectra results, which permits fluorescein to serve as both an energy transfer donor and acceptor (30). Consequently, two proximal fluorescein molecules will undergo nonradiative energy transfer (homotransfer) much like that commonly measured using different donor and acceptor probes (heterotransfer). In the case of homotransfer the accompanying loss in the fluorescence polarization of fluorescein with increasing probe stoichiometry (increased FRET) provides a convenient means to assess intermolecular distances (30, 31, 53).

To detect any changes in spatial separation between nucleotide sites within Ca-ATPase polypeptide chains, FRET-induced depolarization of FITC was measured and plotted as changes in molecular anisotropy in the form of a Perrin equation, i.e.,  $(1/P - 1/3)^{-1}$  (Figure 5). A progressive decrease in the anisotropy is observed as the fraction of FITC site occupation is increased, consistent with FRET-induced depolarization. Detergent solubilization of vesicles with C<sub>12</sub>E<sub>8</sub> under conditions that produce monomeric Ca-ATPase results in substantially larger values for molecular anisotropy, which are independent of label stoichiometry, demonstrating that the measured depolarization is entirely due to FRET between sites on neighboring polypeptide chains. Upon PKA phosphorylation of PLB in native cardiac microsomes, the observed depolarization exhibits anisotropy values that are further decreased at each label stoichiometry relative to those measured prior to PLB phosphorylation, suggesting phosphorylation-induced increases in FRET, i.e., closer FITC proximity.

Similarly, with IAF, increasing probe modification also results in FRET-induced depolarization, which is also entirely due to FRET as evidenced by the absence of any depolarization at each fractional label stoichiometry when SR vesicles are solubilized with detergent (Figure 5, lower panel). However, after PKA-induced phosphorylation of PLB there is an increase in anisotropy values observed at each probe stoichiometry as compared with nonphosphorylated PLB, indicative of phosphorylation-induced decreases in




FIGURE 5: PLB modulates spatial arrangement of Ca-ATPase polypeptide chains. Anisotropy  $(1/P - 1/3)^{-1}$  of FITC- (top panel) or IAF- (bottom panel) labeled Ca-ATPase in cardiac SR microsomes (0.1 mg/mL) as a function of fractional labeling ( $f$ ) of the probe sites (i.e., Lys<sup>514</sup> or Cys<sup>674</sup>) (25). The maximal labeling stoichiometry is  $3.4 \pm 0.1$  nmol of FITC or  $3.7 \pm 0.2$  nmol of IAF per milligram of microsomal protein (see Figure S1 in Supporting Information). Anisotropy was measured for 100  $\mu$ g of microsomes/mL in 20 mM MOPS (pH 7.0), 0.1 M KCl, 5 mM MgCl<sub>2</sub>, 0.1 mM EGTA, and 0.11 mM CaCl<sub>2</sub> ( $Ca_{free}$  is 0.5  $\mu$ M) in the absence (open symbols) or presence (closed symbols) of PKA (80  $\mu$ g/mL), cAMP (1  $\mu$ M), and ATP (0.1 mM) before (circles) and after (squares) solubilization with C<sub>12</sub>E<sub>8</sub> (6 mM). Excitation was at 485 nm, and fluorescence emission was measured using a Schott OG530 cutoff filter. Lines represent nonlinear least-squares fits to the data according to the models for interactions between neighboring fluorophores (see eq 2 in Experimental Procedures).

FRET, i.e., greater distances between IAF molecules on neighboring Ca-ATPase polypeptide chains. Thus, phosphorylation of PLB induces opposite effects on the average distance between neighboring FITC molecules versus that of neighboring IAF molecules, suggesting a reorientation of nearby Ca-ATPase polypeptide chains with respect to one another.

For both FITC and IAF, phosphorylation-dependent changes in anisotropy are fully reversible with subsequent dephosphorylation of PLB mediated by alkaline phosphatase, which hydrolyzes the phosphoester linkage at Ser<sup>16</sup> in PLB (Figure 6). Of note, the anisotropy value at the lowest labeling stoichiometry for FITC-labeled Ca-ATPase, where FRET-induced depolarization is minimal, is near the theoretical maximum (rigid limit) of 0.6 (Figure 5A), consistent with a highly ordered environment of fluorescein in the nucleotide binding cleft (45, 46). In comparison, the anisotropy of IAF is substantially smaller than that of FITC (Figure 5B), indicating some extent of rotational mobility of IAF that is consistent with its surface exposure bound to Cys<sup>674</sup> within a loop structure (Figure 1). PLB phosphorylation does not alter the average lifetime of either fluorophore or their respective solvent accessibilities, indicating that there are no substantial changes in the polarity or steric restrictions within the immediate environment of either fluorescein probe (Table 1). Thus, the PKA-dependent increases in homotransfer between FITC chromophores, with corresponding decreases between IAF chromophores, suggest spatial reorientations




FIGURE 6: Reversible PLB phosphorylation state. Fluorescence polarization of FITC- (top) or IAF- (bottom) labeled Ca-ATPase (2.0 nmol/mg or  $F = 0.6$ ) measured (i) prior to activation (control), (ii) following activation by addition of cAMP-dependent protein kinase (80  $\mu$ g/mL), 5 mM ATP, and 1  $\mu$ M cAMP (+PKA), and (iii) subsequent to treatment of activated microsomes with the PKA inhibitor calyculin (50 nM) and alkaline phosphatase (5 units/mL) (+phosphatase). Asterisks represent statistically significant differences ( $p < 0.005$ ) in polarization values relative to controls.

of domain elements in neighboring Ca-ATPase polypeptide chains rather than changes in local conformation at the probe site.

Quantitative information regarding intermolecular distances and effective dipolar orientations between fluorescein moieties of FITC and IAF bound to Ca-ATPase polypeptide chains can be obtained by fitting the Perrin plots to a series of physical models in which the oligomeric state is set at various integer values (see eq 2 in Experimental Procedures) (Figure 5) (20, 30, 31). Optimal nonlinear least-squares fits to the data, assessed by the reduced chi-squared values ( $\chi_R^2$ ), indicate that the average oligomeric state of the Ca-ATPase, regardless of the phosphorylation state of PLB, is a dimer. Upon PLB phosphorylation, there are no significant changes in the effective dipolar orientation between the fluorescein chromophores on proximal Ca-ATPase polypeptide chains (Table 1). These latter results are consistent with the presence of multiple dipole moments within individual fluorescein molecules and large amplitude domain motions of the Ca-ATPase, which are expected to minimize the sensitivity of energy transfer to changes in probe orientation (54–57). In comparison, there are significant changes in the intermolecular distance between fluorescein chromophores following the phosphorylation of PLB, which are apparent from the error surfaces associated with fitting the experimental data to a model (Figure 7). For example, upon PLB phosphorylation the mean distances recovered between FITC fluorophores bound to the N-domains on neighboring Ca-ATPase molecules decrease by  $4 \pm 2$  Å, from  $24 \pm 2$  Å to  $20 \pm 1$  Å (Table 1). In contrast, in skeletal SR the spatial separation between FITC labeling sites on neighboring Ca-ATPase polypeptide chains was determined to be  $42 \pm 4$  Å, in good agreement with previous measurements of 44 Å in skeletal SR (see Figure S2 in Supporting Information) (30). Thus these differences in FITC–FITC distances suggest conformational differences in Ca-ATPase dimers that bring neigh-



Table 1: Spatial Separation between Fluorescein Binding Sites in Ca-ATPase Oligomeric Complex<sup>a</sup>

sample	$\langle\tau_2\rangle$ (ns)	$K_{SV}$ (M <sup>-1</sup> )		$\theta_{av}$ (deg)	$r_{av}$ (Å)	$n$
		iodide	acrylamide			
FITC (N-domain)						
nonactivated	3.8 ± 0.1	3.07 ± 0.07	0.37 ± 0.01	40 ± 2	24 ± 2	2
PKA activated	3.4 ± 0.1	3.04 ± 0.02	0.37 ± 0.01	39 ± 2	20 ± 1	2
IAF (P-domain)						
nonactivated	3.5 ± 0.1	9.9 ± 0.3	1.22 ± 0.06	38 ± 2	31 ± 2	2
PKA activated	3.4 ± 0.1	9.6 ± 0.3	1.25 ± 0.07	35 ± 3	40 ± 2	2

<sup>a</sup> Solution conditions are as described in the legend to Figure 4. Average lifetimes ( $\tau$ ) were measured as previously described (56), where the frequency response data were fit to a sum of two exponentials, where  $\tau_1 = 1.7$  ns and  $\tau_2 = 3.8$  ns. The Stern–Volmer solvent accessibility ( $K_{SV}$ ) measured in the presence of charged (iodide) and neutral (acrylamide) quenchers was fit using eq 5. The average donor–acceptor distance ( $r_{av}$ ), the effective angle between the donor and acceptor absorption dipoles ( $\theta_{av}$ ), and the oligomeric size ( $n$ ) were obtained from fits to the data in Figure 5, as described in Experimental Procedures.




FIGURE 7: Phosphorylation of PLB differentially modifies spatial separation between N- and P-domains of Ca-ATPase polypeptide chains in the oligomeric complex. Depiction of error surfaces prior to (solid lines) or following (dashed lines) the phosphorylation of PLB by PKA for the distance ( $r$ ) between FITC (left) or IAF (right) chromophores bound to proximal SERCA2a isoforms of the Ca-ATPase polypeptide chains labeled at Lys<sup>514</sup> or Cys<sup>670</sup>, respectively. Normalized  $\chi^2_N$  values were determined from nonlinear least-squares fits to the data depicted in Figure 5 following incremental adjustment of the spatial separation (distance) between either FITC (left) or IAF (right) chromophores. The horizontal dashed line at  $\chi^2_N = 1.287$  corresponds to the  $F$ -statistic, which represents one standard deviation relative to the best fit to the data. Experimental conditions are as described in the legend to Figure 5.

boring N-domains into closer proximity in cardiac SR as compared with those in skeletal SR.

The intermolecular distances between IAF fluorophores bound to the P-domains on neighboring Ca-ATPase molecules are increased by  $9 \pm 3$  Å upon PLB phosphorylation, from  $31 \pm 2$  Å to  $40 \pm 2$  Å (Figure 7). Comparative measurements of IAF–IAF distances in skeletal SR were less informative, since SERCA1 contains two IAF reactive sites (Cys<sup>670</sup> and Cys<sup>674</sup>) resulting in a substantial contribution of intramolecular FRET to the measured depolarization that precludes recovery of a single intersubunit distance (25) (Figure S2 in Supporting Information).

## DISCUSSION

We have examined the role of oligomeric interactions between individual Ca-ATPase polypeptide chains in native cardiac SR membranes and their modulation by the phosphorylation state of PLB. Assessing both functional and spatial interactions between Ca-ATPases, we find that prior to phosphorylation of PLB the active sites of neighboring

Ca-ATPase monomers are uncoupled and function independently. However, the release of PLB inhibition of the Ca-ATPase, by either PKA-mediated PLB phosphorylation or heparin treatment, restores conformational coupling between individual Ca-ATPase polypeptide chains, which is accompanied by a reorientation of Ca-ATPase proteins within a dimeric unit. This reorientation is manifested by large-scale protein rearrangements that result in a 9 Å increase in the distance between labeled sites (Cys<sup>674</sup>) on the P-domain concomitant with a 4 Å decrease between labeled sites (Lys<sup>514</sup>) on the N-domain of SERCA2a in cardiac SR (Figure 7). These measurements indicate an important contribution to calcium transport of coupled domain movements between oligomeric complexes of the Ca-ATPase, in agreement with earlier kinetic measurements, suggesting that unphosphorylated PLB interferes with oligomeric interactions within Ca-ATPases important for calcium transport (16, 21). Further, PLB binding to the Ca-ATPase increases conformational barriers associated with the large-scale domain movements of the Ca-ATPase necessary for calcium activation.

Whereas prior measurements have recognized the presence of oligomeric interactions between Ca-ATPase proteins in both skeletal and cardiac membranes, their functional importance has remained uncertain based on observations that individual Ca-ATPase monomers retain independent active sites and functional competence following disruption of protein–protein contact interactions with detergent solubilization (49). Furthermore, much work aimed at understanding the regulation of the Ca-ATPase by PLB has been limited to the study of the each of these proteins in isolation, from, e.g., their individual high-resolution structures and mutational analysis to identify key amino acids associated with the transport mechanism (58). More recently, the development of robust expression systems for the Ca-ATPase has permitted detailed functional measurements of the effect of PLB on SERCA2a function, identifying an important role for PLB in modulating the allosteric coupling between Ca-ATPase polypeptide chains within an oligomeric complex to affect rates of phosphoenzyme decomposition and hydrolysis (16, 21, 59–63). For example, Mahaney and Froehlich report very similar kinetic behavior between the monomeric form of the SERCA1 isoform of the Ca-ATPase in skeletal SR following detergent solubilization and the SERCA2a isoform of the Ca-ATPase coexpressed with PLB in insect microsomes or in cardiac SR (21, 62). In contrast, either upon the expression of SERCA2a in the absence of PLB or following the phosphorylation of PLB by PKA, the transient kinetics of the Ca-ATPase are similar to that

observed for oligomeric complexes of SERCA1 (21). These latter results are consistent with the findings of the present study, which demonstrate that PLB modulates functional interactions between Ca-ATPase polypeptide chains within a dimeric protein complex (Figures 4–7, Table 1). Following the phosphorylation of PLB by PKA, we likewise observe a functional coupling between Ca-ATPase polypeptide chains similar to that observed in skeletal SR (Figure 4) (51). Combined, these results indicate the importance of the oligomeric complex involving two Ca-ATPase polypeptide chains in association with PLB, where the functional coupling between nucleotide binding sites is essential for maximal ATPase activity.

The ability of unphosphorylated PLB to uncouple the allosteric cooperativity between Ca-ATPase polypeptide chains acts to slow the rate-limiting step involving phosphoenzyme decomposition and is consistent with the importance of large-scale protein domain motions in the mechanism of calcium transport (32). Indeed, it has been noted that large-scale protein motions commonly underlie both allosteric cooperativity and catalysis and are, in many cases, rate limiting. In this respect, prior measurements have demonstrated (i) that large-scale domain motions of the Ca-ATPase are rate limiting (64) and (ii) that PLB binding to the N-domain of the Ca-ATPase restricts domain mobility (10, 15, 56, 65–67). Previous work has demonstrated that upon phosphorylation of PLB there is an associated stabilization of the hinge domain of PLB that results in a shortening of the overall dimensions of the cytosolic domain, thus resulting in release of inhibitory interactions between PLB and the N-domain of the Ca-ATPase (1, 5–7, 67–70). Findings that a single PLB molecule interacting with two Ca-ATPase polypeptide chains is sufficient to fully inhibit transport activity (18, 19) lend further support to the hypothesis that phosphorylation of PLB acts to release structural constraints associated with oligomeric interactions between Ca-ATPase polypeptide chains that are necessary for optimal activity.

Understanding molecular mechanisms relating how PLB-dependent conformational changes in complex with the Ca-ATPase modulate function is currently limited by the availability of only a single low-resolution structure of a dimeric complex; this structure depicts a single PLB bound to both Ca-ATPase polypeptide chains in the homodimeric protein complex (18, 71). Building upon these earlier results, we have modeled the interactions between Ca-ATPase polypeptide chains through a series of molecular docking calculations using three-dimensional structures of the SERCA1 isoform of the Ca-ATPase (i.e., 1kju.pdb) and, additionally, taking into consideration potential interaction sites with PLB through separate docking calculations. An optimal configuration involving the docking of two monomers of the Ca-ATPase was evaluated based on electrostatics, desolvation energies, and shape complementarity. Among 2000 structures generated, only two models met the criteria described in Experimental Procedures. One of these (Figure 8) better reproduced the residue–residue distance constraints from FRET experiments (Table 1) and allowed PLB–Ca-ATPase interactions (see Figure S4 in Supporting Information for a comparison of the two structure models).




FIGURE 8: Proposed structural model for the Ca-ATPase homodimer. The two monomers of the Ca-ATPase are related by a 2-fold rotational center of symmetry perpendicular to the cytoplasmic membrane. Top (A) and longitudinal (B) views of the dimer built from the crystallographic structure of SERCA1, i.e., 1kju.pdb. Domains are colored as in Figure 1. The lowest energy PLB conformer from the NMR ensemble (1fjk.pdb) was superimposed on the lowest energy docked PLB conformer (domains Ia and II; Figure S3 in Supporting Information) and does not consider known large-scale changes in the orientation of the N-domain of the Ca-ATPase upon PLB binding (10, 56, 67). The NMR-derived and the predicted PLB conformers are shown in yellow and green cartoon helices, respectively. Amino acid residues involved in PLB–Ca-ATPase cross-linking are represented as space-filling structures: orange for PLB and red for the Ca-ATPase. PLB residues have been marked with the prime symbol.

PLB interactions with the Ca-ATPase were modeled separately by docking known structures of PLB onto monomeric forms of the SERCA1 Ca-ATPase obtained for the apo form and following calcium activation (i.e., 2agv.pdb and 1su4.pdb). The transmembrane helix (i.e., domain II) and the cytoplasmic N-terminal portion (domain Ia) of PLB were docked separately to eliminate any bias imposed by the initial configuration of the flexible interhelical loop (domain Ib), treating individual helical domains as rigid bodies (see Experimental Procedures). The two extremes of the most populated conformational cluster of structures show that there is substantial uniformity in the docking of transmembrane and cytosolic helices; in particular, the transmembrane helix of PLB binds within the groove formed by Ca-ATPase transmembrane helices M4, M6, and M9, as previously described (12, 13) (Figure S3 in Supporting Information).



Placement of these docked PLB complexes onto the structures of calculated homodimers of the Ca-ATPase suggests that the membrane spanning helix of PLB is located within the inner face of the complex between proximal Ca-ATPase polypeptide chains (Figure 8). Within the homodimeric complex (Figure 8), Ca-ATPase monomers are related by a 2-fold rotational center of symmetry perpendicular to the plane of the membrane in agreement with EM studies of cocrystals of Ca-ATPase and PLB (Figure 8). Molecular interactions occur primarily through residues in the N-domain, with some involvement of P-domain side chains that are reflected by large reductions in calculated *B*-factors for the homodimeric complex (Figure S5 in Supporting Information). This model, based on individual high-resolution structures of SERCA1 and PLB, can be taken as a starting point for defining the structure of Ca-ATPase–PLB oligomers. Use of this molecular docking algorithm, based on rigid body structures, does not take into account internal protein dynamics and induced fit of dimer units, nor does it consider large changes in domain positions of the Ca-ATPase upon association with PLB (10, 56). Nevertheless, this model (Figure 8), derived from docking of SERCA2 structures, exhibits a 37 Å spatial separation between  $\alpha$ -carbons of Lys<sup>515</sup>, comparing favorably with the measured distances between FITC chromophores ( $42 \pm 2$  Å) on neighboring Ca-ATPase polypeptide chains in skeletal SR (Figure S2 in Supporting Information), but fits less well to the smaller corresponding distance (Table 1) measured by FRET for cardiac SR ( $24 \pm 2$  Å). We suggest that PLB, present in cardiac but not skeletal SR, is primarily responsible for these inherent differences and that PLB induces domain and concomitant dimeric rearrangements of the Ca-ATPase. The substantial homology (84% sequence identity) between SERCA2a and SERCA1 isoforms and the ability of PLB to fully regulate SERCA1 in both coreconstituted or coexpression systems suggest that isoform differences can be ruled out as an explanation for the structural differences in Ca-ATPase oligomers (1, 63). Previous reports have demonstrated that association of PLB with sites in the N-domain of the Ca-ATPase induces large domain reorientations that are sensitive to the phosphorylation of PLB which can bring nucleotide binding sites into closer proximity (10, 56, 67, 69). Indeed, FRET measurements between sites within cytosolic and transmembrane domains of PLB have demonstrated that this distance remains the same whether PLB is reconstituted into proteoliposomes alone or coreconstituted with the Ca-ATPase, providing further evidence that the Ca-ATPase undergoes structural changes that accommodate a compact and ordered PLB structure (7).

In conclusion, this model shows a potential mechanism for the functional coupling between Ca-ATPase active sites through the interaction of regions of the N- and P-domains of proximal Ca-ATPase polypeptide chains; furthermore, this model is compatible with modulation of this coupling by PLB through its modification of the Ca-ATPase dimeric interface to permit independent catalytic motions associated with transport function. This model is matched to experimental data taken under quiescent conditions and therefore reflects an oligomeric state that exists prior to the addition of ATP and enzymatic cycling; thus the model presented may constitute only one enzyme state with other possible arrangements of the chains occurring during cycling. Future

work should combine experimental data taken under conditions that stabilize additional enzyme states compared with molecular modeling of the PLB–Ca-ATPase oligomers that considers molecular dynamics of Ca-ATPase domain reorientations.

## SUPPORTING INFORMATION AVAILABLE

Inactivation and FRET data for the SERCA1 isoform of the Ca-ATPase in skeletal SR as well as additional molecular models and pdb coordinates from docking calculations and normal-mode analysis *B*-factors. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## REFERENCES

- Li, J., Bigelow, D. J., and Squier, T. C. (2004) Conformational changes within the cytosolic portion of phospholamban upon release of Ca-ATPase inhibition. *Biochemistry* 43, 3870–3879.
- Negash, S., Yao, Q., Sun, H., Li, J., Bigelow, D. J., and Squier, T. C. (2000) Phospholamban remains associated with the  $\text{Ca}^{2+}$ - and  $\text{Mg}^{2+}$ -dependent ATPase following phosphorylation by cAMP-dependent protein kinase. *Biochem. J.* 351, 195–205.
- Asahi, M., McKenna, E., Kurzydowski, K., Tada, M., and MacLennan, D. H. (2000) Physical interactions between phospholamban and sarco(endo)plasmic reticulum  $\text{Ca}^{2+}$ -ATPases are dissociated by elevated  $\text{Ca}^{2+}$ , but not by phospholamban phosphorylation, vanadate, or thapsigargin, and are enhanced by ATP. *J. Biol. Chem.* 275, 15034–15038.
- Chen, B., Mahaney, J. E., Mayer, M. U., Bigelow, D. J., and Squier, T. C. (2008) Concerted but noncooperative activation of nucleotide and actuator domains of the Ca-ATPase upon calcium binding. *Biochemistry* 47, 12448–12456.
- Li, J., Boschek, C. B., Xiong, Y., Sacksteder, C. A., Squier, T. C., and Bigelow, D. J. (2005) Essential role for Pro21 in phospholamban for optimal inhibition of the Ca-ATPase. *Biochemistry* 44, 16181–16191.
- Li, J., Bigelow, D. J., and Squier, T. C. (2003) Phosphorylation by cAMP-dependent protein kinase modulates the structural coupling between the transmembrane and cytosolic domains of phospholamban. *Biochemistry* 42, 10674–10682.
- Li, J., Xiong, Y., Bigelow, D. J., and Squier, T. C. (2004) Phospholamban binds in a compact and ordered conformation to the Ca-ATPase. *Biochemistry* 43, 455–463.
- Ha, K. N., Traaseth, N. J., Verardi, R., Zamoon, J., Cembran, A., Karim, C. B., Thomas, D. D., and Veglia, G. (2007) Controlling the inhibition of the sarcoplasmic  $\text{Ca}^{2+}$ -ATPase by tuning phospholamban structural dynamics. *J. Biol. Chem.* 282, 37205–37214.
- Morita, T., Hussain, D., Asahi, M., Tsuda, T., Kurzydowski, K., Toyoshima, C., and MacLennan, D. H. (2008) Interaction sites among phospholamban, sarcolipin, and the sarco(endo)plasmic reticulum  $\text{Ca}^{2+}$ -ATPase. *Biochem. Biophys. Res. Commun.* 369, 188–194.
- James, P., Inui, M., Tada, M., Chiesi, M., and Carafoli, E. (1989) Nature and site of phospholamban regulation of the  $\text{Ca}^{2+}$  pump of sarcoplasmic reticulum. *Nature* 342, 90–92.
- Chen, Z., Akin, B. L., Stokes, D. L., and Jones, L. R. (2006) Cross-linking of C-terminal residues of phospholamban to the  $\text{Ca}^{2+}$  pump of cardiac sarcoplasmic reticulum to probe spatial and functional interactions within the transmembrane domain. *J. Biol. Chem.* 281, 14163–14172.
- Toyoshima, C., Asahi, M., Sugita, Y., Khanna, R., Tsuda, T., and MacLennan, D. H. (2003) Modeling of the inhibitory interaction of phospholamban with the  $\text{Ca}^{2+}$  ATPase. *Proc. Natl. Acad. Sci. U.S.A.* 100, 467–472.
- Seidel, K., Andronesi, O. C., Krebs, J., Griesinger, C., Young, H. S., Becker, S., and Baldus, M. (2008) Structural characterization of  $\text{Ca}^{2+}$ -ATPase-bound phospholamban in lipid bilayers by solid-state nuclear magnetic resonance (NMR) spectroscopy. *Biochemistry* 47, 4369–4376.
- Hutter, M. C., Krebs, J., Meiler, J., Griesinger, C., Carafoli, E., and Helms, V. (2002) A structural model of the complex formed by phospholamban and the calcium pump of sarcoplasmic reticulum obtained by molecular mechanics. *ChemBioChem* 3, 1200–1208.

15. MacLennan, D. H., and Kranias, E. G. (2003) Phospholamban: a crucial regulator of cardiac contractility. *Nat. Rev. Mol. Cell Biol.* **4**, 566–577.
16. Waggoner, J. R., Huffman, J., Froehlich, J. P., and Mahaney, J. E. (2007) Phospholamban inhibits Ca-ATPase conformational changes involving the E2 intermediate. *Biochemistry* **46**, 1999–2009.
17. Chen, Z., Akin, B. L., and Jones, L. R. (2007) Mechanism of reversal of phospholamban inhibition of the cardiac  $\text{Ca}^{2+}$ -ATPase by protein kinase A and by anti-phospholamban monoclonal antibody 2D12. *J. Biol. Chem.* **282**, 20968–20976.
18. Young, H. S., Jones, L. R., and Stokes, D. L. (2001) Locating phospholamban in co-crystals with  $\text{Ca}^{2+}$ -ATPase by cryoelectron microscopy. *Biophys. J.* **81**, 884–894.
19. Ferrington, D. A., Yao, Q., Squier, T. C., and Bigelow, D. J. (2002) Comparable levels of Ca-ATPase inhibition by phospholamban in slow-twitch skeletal and cardiac sarcoplasmic reticulum. *Biochemistry* **41**, 13289–13296.
20. Yao, Q., Chen, L. T., Li, J., Brungardt, K., Squier, T. C., and Bigelow, D. J. (2001) Oligomeric interactions between phospholamban molecules regulate Ca-ATPase activity in functionally reconstituted membranes. *Biochemistry* **40**, 6406–6413.
21. Mahaney, J. E., Albers, R. W., Waggoner, J. R., Kutchai, H. C., and Froehlich, J. P. (2005) Intermolecular conformational coupling and free energy exchange enhance the catalytic efficiency of cardiac muscle SERCA2a following the relief of phospholamban inhibition. *Biochemistry* **44**, 7713–7724.
22. Negash, S., Chen, L. T., Bigelow, D. J., and Squier, T. C. (1996) Phosphorylation of phospholamban by cAMP-dependent protein kinase enhances interactions between Ca-ATPase polypeptide chains in cardiac sarcoplasmic reticulum membranes. *Biochemistry* **35**, 11247–11259.
23. Lanzetta, P. A., Alvarez, L. J., Reinach, P. S., and Candia, O. A. (1979) An improved assay for nanomole amounts of inorganic phosphate. *Anal. Biochem.* **100**, 95–97.
24. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* **227**, 680–685.
25. Bishop, J. E., Squier, T. C., Bigelow, D. J., and Inesi, G. (1988) (Iodoacetamido)fluorescein labels a pair of proximal cysteines on the  $\text{Ca}^{2+}$ -ATPase of sarcoplasmic reticulum. *Biochemistry* **27**, 5233–5240.
26. Pick, U., and Karlisch, S. J. (1980) Indications for an oligomeric structure and for conformational changes in sarcoplasmic reticulum  $\text{Ca}^{2+}$ -ATPase labelled selectively with fluorescein. *Biochim. Biophys. Acta* **626**, 255–261.
27. Gratton, E., and Limkeman, M. (1983) A continuously variable frequency cross-correlation phase fluorometer with picosecond resolution. *Biophys. J.* **44**, 315–324.
28. Bevington, P. (1969) *Data Reduction and Error Analysis for the Physical Sciences*, pp 56–64, McGraw-Hill, New York.
29. Lakowicz, J. (1999) *Principles of Fluorescence Spectroscopy*, 2nd ed., Kluwer Academic/Plenum Publishers, New York.
30. Highsmith, S., and Cohen, J. A. (1987) Spatial organization of CaATPase molecules in sarcoplasmic reticulum vesicles. *Biochemistry* **26**, 154–161.
31. Runnels, L. W., and Scarlata, S. F. (1995) Theory and application of fluorescence homotransfer to melittin oligomerization. *Biophys. J.* **69**, 1569–1583.
32. Xu, C., Rice, W. J., He, W., and Stokes, D. L. (2002) A structural model for the catalytic cycle of  $\text{Ca}^{2+}$ -ATPase. *J. Mol. Biol.* **316**, 201–211.
33. Stokes, D. L., Pomfret, A. J., Rice, W. J., Graves, J. P., and Young, H. S. (2006) Interactions between  $\text{Ca}^{2+}$ -ATPase and the pentameric form of phospholamban in two-dimensional co-crystals. *Biophys. J.* **90**, 4213–4223.
34. Chen, R., and Weng, Z. P. (2002) Docking unbound proteins using shape complementarity, desolvation, and electrostatics. *Proteins* **47**, 281–294.
35. Chen, R., and Weng, Z. (2003) A novel shape complementarity scoring function for protein-protein docking. *Proteins* **51**, 397–408.
36. Toyoshima, C., Nakasako, M., Nomura, H., and Ogawa, H. (2000) Crystal structure of the calcium pump of sarcoplasmic reticulum at 2.6 Å resolution. *Nature* **405**, 647–655.
37. Obara, K., Miyashita, N., Xu, C., Toyoshima, I., Sugita, Y., Inesi, G., and Toyoshima, C. (2005) Structural role of countertransport revealed in  $\text{Ca}^{2+}$  pump crystal structure in the absence of  $\text{Ca}^{2+}$ . *Proc. Natl. Acad. Sci. U.S.A.* **102**, 14489–14496.
38. Lamberth, S., Schmid, H., Muenchbach, M., Vorherr, T., Krebs, J., Carafoli, E., and Griesinger, C. (2000) Structural role of countertransport revealed in  $\text{Ca}^{2+}$  pump crystal structure in the absence of  $\text{Ca}^{2+}$ . *Proc. Natl. Acad. Sci. U.S.A.* **102**, 14489–14496.
39. Lamberth, S., Schmid, H., Muenchbach, M., Vorherr, T., Krebs, J., Carafoli, E., and Griesinger, C. (2000) NMR solution structure of phospholamban. *Helv. Chim. Acta* **83**, 2141–2152.
40. Morris, G., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K., and Olson, A. J. (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. *J. Comput. Chem.* **19**, 1639–1662.
41. Yang, L., Tan, C. H., Hsieh, M. J., Wang, J., Duan, Y., Cieplak, P., Caldwell, J., Kollman, P. A., and Luo, R. (2006) New-generation amber united-atom force field. *J. Phys. Chem. B* **110**, 13166–13176.
42. Soares, T. A., Goodsell, D. S., Briggs, J. M., Ferreira, R., and Olson, A. J. (1999) Docking of 4-oxalocrotonate tautomerase substrates: Implications for the catalytic mechanism. *Biopolymers* **50**, 319–328.
43. Soares, T. A., Goodsell, D. S., Ferreira, R., Olson, A. J., and Briggs, J. M. (2000) Ionization state and molecular docking studies for the macrophage migration inhibitory factor: the role of lysine 32 in the catalytic mechanism. *J. Mol. Recognit.* **13**, 146–156.
44. Mitchinson, C., Wilderspin, A. F., Trinnaman, B. J., and Green, N. M. (1982) Identification of a labelled peptide after stoichiometric reaction of fluorescein isothiocyanate with the  $\text{Ca}^{2+}$ -dependent adenosine triphosphatase of sarcoplasmic reticulum. *FEBS Lett.* **146**, 87–92.
45. Kirley, T. L., Wang, T., Wallick, E. T., and Lane, L. K. (1985) Homology of ATP binding sites from  $\text{Ca}^{2+}$  and (Na, K)-ATPases: comparison of the amino acid sequences of fluorescein isothiocyanate labeled peptides. *Biochem. Biophys. Res. Commun.* **130**, 732–738.
46. Tate, C. A., Shin, G., Walseth, T. F., Taffet, G. E., Bick, R. J., and Entman, M. L. (1991) Nucleotide specificity of cardiac sarcoplasmic reticulum. Inhibition of GTPase activity by ATP analogue in fluorescein isothiocyanate-modified calcium ATPase. *J. Biol. Chem.* **266**, 16165–16170.
47. Bodley, A. L., and Jencks, W. P. (1987) Acetyl phosphate as a substrate for the calcium ATPase of sarcoplasmic reticulum. *J. Biol. Chem.* **262**, 13997–14004.
48. Teruel, J. A., and Inesi, G. (1988) Roles of phosphorylation and nucleotide binding domains in calcium transport by sarcoplasmic reticulum adenosinetriphosphatase. *Biochemistry* **27**, 5885–5890.
49. Andersen, J. P. (1989) Monomer-oligomer equilibrium of sarcoplasmic reticulum Ca-ATPase and the role of subunit interaction in the  $\text{Ca}^{2+}$  pump mechanism. *Biochim. Biophys. Acta* **988**, 47–72.
50. Xu, Z. C., and Kirchberger, M. A. (1989) Modulation by poly-electrolytes of canine cardiac microsomal calcium uptake and the possible relationship to phospholamban. *J. Biol. Chem.* **264**, 16644–16651.
51. Squier, T. C., Hughes, S. E., and Thomas, D. D. (1988) Rotational dynamics and protein-protein interactions in the Ca-ATPase mechanism. *J. Biol. Chem.* **263**, 9162–9170.
52. Yao, Q., Chen, L. T., and Bigelow, D. J. (1998) Affinity purification of the Ca-ATPase from cardiac sarcoplasmic reticulum membranes. *Protein Expression Purif.* **13**, 191–197.
53. Erijman, L., and Weber, G. (1991) Oligomeric protein associations: transition from stochastic to deterministic equilibrium. *Biochemistry* **30**, 1595–1599.
54. Wu, P., and Brand, L. (1992) Orientation factor in steady-state and time-resolved resonance energy transfer measurements. *Biochemistry* **31**, 7939–7947.
55. Chen, B., Squier, T. C., and Bigelow, D. J. (2004) Calcium activation of the Ca-ATPase enhances conformational heterogeneity between nucleotide binding and phosphorylation domains. *Biochemistry* **43**, 4366–4374.
56. Negash, S., Huang, S., and Squier, T. C. (1999) Rearrangement of domain elements of the Ca-ATPase in cardiac sarcoplasmic reticulum membranes upon phospholamban phosphorylation. *Biochemistry* **38**, 8150–8158.
57. Huang, S., and Squier, T. C. (1998) Enhanced rotational dynamics of the phosphorylation domain of the Ca-ATPase upon calcium activation. *Biochemistry* **37**, 18064–18073.
58. Toyoshima, C. (2008) Structural aspects of ion pumping by  $\text{Ca}^{2+}$ -ATPase of sarcoplasmic reticulum. *Arch. Biochem. Biophys.* **476**, 3–11.
59. Froehlich, J. P., and Heller, P. F. (1985) Transient-state kinetics of the ADP-insensitive phosphoenzyme in sarcoplasmic reticulum:

- implications for transient-state calcium translocation. *Biochemistry* 24, 126–136.
60. Froehlich, J. P., Taniguchi, K., Fendler, K., Mahaney, J. E., Thomas, D. D., and Albers, R. W. (1997) Complex kinetic behavior in the Na, K- and Ca-ATPases. Evidence for subunit-subunit interactions and energy conservation during catalysis. *Ann. N.Y. Acad. Sci.* 834, 280–296.
61. Froehlich, J. P., and Taylor, E. W. (1975) Transient state kinetic studies of sarcoplasmic reticulum adenosine triphosphatase. *J. Biol. Chem.* 250, 2013–2021.
62. Mahaney, J. E., Thomas, D. D., and Froehlich, J. P. (2004) The time-dependent distribution of phosphorylated intermediates in native sarcoplasmic reticulum  $\text{Ca}^{2+}$ -ATPase from skeletal muscle is not compatible with a linear kinetic model. *Biochemistry* 43, 4400–4416.
63. Mahaney, J. E., Autry, J. M., and Jones, L. R. (2000) Kinetics studies of the cardiac Ca-ATPase expressed in Sf21 cells: new insights on Ca-ATPase regulation by phospholamban. *Biophys. J.* 78, 1306–1323.
64. Goodey, N. M., and Benkovic, S. J. (2008) Allosteric regulation and catalysis emerge via a common route. *Nat. Chem. Biol.* 4, 474–482.
65. Squier, T. C., Bigelow, D. J., and Thomas, D. D. (1988) Lipid fluidity directly modulates the overall protein rotational mobility of the Ca-ATPase in sarcoplasmic reticulum. *J. Biol. Chem.* 263, 9178–9186.
66. Bigelow, D. J., Squier, T. C., and Thomas, D. D. (1986) Temperature dependence of rotational dynamics of protein and lipid in sarcoplasmic reticulum membranes. *Biochemistry* 25, 194–202.
67. Pantano, S., and Carafoli, E. (2007) The role of phosphorylation on the structure and dynamics of phospholamban: a model from molecular simulations. *Proteins* 66, 930–940.
68. Bigelow, D. J., and Squier, T. C. (2005) Redox modulation of cellular signaling and metabolism through reversible oxidation of methionine sensors in calcium regulatory proteins. *Biochim. Biophys. Acta* 1703, 121–134.
69. Bigelow, D. J., and Squier, T. C. (2006) Coil-to-helix transition within phospholamban underlies release of Ca-ATPase inhibition in response to beta-adrenergic signaling. *Curr. Enzyme Inhib.* 2, 19–27.
70. Sugita, Y., Miyashita, N., Yoda, T., Ikeguchi, M., and Toyoshima, C. (2006) Structural changes in the cytoplasmic domain of phospholamban by phosphorylation at Ser16: a molecular dynamics study. *Biochemistry* 45, 11752–11761.
71. Stokes, D. L., Pomfret, A. J., Rice, W. J., Glaves, J. P., and Young, H. S. (2006) Interactions between  $\text{Ca}^{2+}$ -ATPase and the pentameric form of phospholamban in two-dimensional co-crystals. *Biophys. J.* 90, 4213–4223.
72. Sorensen, T. L., Moller, J. V., and Nissen, P. (2004) Phosphoryl transfer and calcium ion occlusion in the calcium pump. *Science* 304, 1672–1675.

BI8021526